Together, our data indicate that not only the mutant or WT status of Rb but also the expression levels of FZR1 and functional activity of the APC/CFZR1 E3 ligase will determine how cancer cells respond to CDK4/6 inhibitor treatment. The gene discussed is RB1; the disease is cancer.